Precision BioSciences Inc. 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL) filed a Current Report on Form 8-K on January 12, 2026. The filing provides preliminary, unaudited financial estimates for the year ended December 31, 2025, and outlines strategic priorities and clinical trial updates for 2026.
Key Financial Metrics
- Cash Position: Approximately $137 million in cash, cash equivalents, and restricted cash as of December 31, 2025.
- Liquidity Runway: Management expects cash to extend through 2028, supported by existing cash, potential licensee consideration, fiscal discipline, and an at-the-market facility.
- Revenue and Profit: The filing does not provide specific values for revenue, profit, cash flow, or margins for the year ended December 31, 2025.
- Debt: No specific debt figures are disclosed in this filing.
Material Changes and Clinical Updates
The filing highlights significant developments in the Company's clinical pipeline rather than historical financial changes:
- ELIMINATE-B Trial (PBGENE-HBV): Additional biopsy data is expected in the first half of 2026. The Company aims to complete dosing for Cohorts 3, 4, and 5 to select an optimal regimen for stopping nucleos(t)ide analog treatment and initiating Part 2 expansion.
- FUNCTION-DMD Trial (Duchenne Muscular Dystrophy): Pending IND clearance, the first patient is expected to dose in late-Q1 or early-Q2 2026, with initial multi-patient data anticipated by year-end 2026.
Guidance, Outlook, and Risks
Management has set strategic priorities for 2026, focusing on operational discipline and clinical progression. The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ due to risks detailed in the Company's 2024 Form 10-K and 2025 Form 10-Q filings. Key uncertainties include regulatory clearance for the FUNCTION-DMD trial and the timing of data releases.
Investor Verification Checklist
- Verify the final audited cash balance for December 31, 2025, once the audit is complete.
- Monitor the timing of the ELIMINATE-B biopsy data release in H1 2026.
- Confirm the status of the investigational new drug (IND) application for the FUNCTION-DMD trial to validate the late-Q1/early-Q2 2026 dosing timeline.
- Review the full press release (Exhibit 99.1) for detailed strategic priorities not fully elaborated in the 8-K text.